These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. FDA notifications. Alternative dosing regimen for atazanavir is approved. AIDS Alert; 2008 Nov; 23(11):129-30. PubMed ID: 19048649 [No Abstract] [Full Text] [Related]
6. FDA notifications. Reyataz is approved for HIV treatment. AIDS Alert; 2003 Sep; 18(9):119-20. PubMed ID: 14686309 [TBL] [Abstract][Full Text] [Related]
7. FDA notifications. FDA approves new atazanavir labeling. AIDS Alert; 2011 Mar; 26(3):33-4. PubMed ID: 21539041 [No Abstract] [Full Text] [Related]
8. HIV therapeutics, continued: another HIV protease inhibitor approved. Laurence J AIDS Read; 2003 Aug; 13(8):355-6. PubMed ID: 14524318 [No Abstract] [Full Text] [Related]
14. BMS-232632, a new protease inhibitor, is taken once daily. Gaylord G Posit Living; 2000 Jul; 9(6):22. PubMed ID: 12492017 [No Abstract] [Full Text] [Related]
17. FDA notifications. Atazanavir capsule label is updated for pediatric patients. AIDS Alert; 2008 May; 23(5):59-60. PubMed ID: 18637262 [No Abstract] [Full Text] [Related]
18. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes. Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415 [TBL] [Abstract][Full Text] [Related]
19. [New treatment options for HIV-infected patients]. Wehr A Dtsch Med Wochenschr; 2004 May; 129(19):1093. PubMed ID: 15174468 [No Abstract] [Full Text] [Related]
20. [Interview with Professor Jürgen Rockstroh, director of the Bonn University Clinic. Atazanavir in general practice]. Rockstroh J MMW Fortschr Med; 2004 Apr; 146 Spec No 1():18-9. PubMed ID: 15373037 [No Abstract] [Full Text] [Related] [Next] [New Search]